title: Triple-negative breast cancer.
abstract: Recent advances in biological characterization of breast cancer have eventually increased our understanding of underlying tumour biology. While for endocrine responsive and Her2-positive disease different molecular targeted therapies are available, up to now no specific targeted approach for triple-negative breast cancer has been developed. Patients with triple-negative disease are at high risk for tumour recurrence. Preclinical and limited clinical data suggest that platinum-based regimens may be the most active conventional chemotherapy, but prospective randomized trials are missing. Bevacizumab and other agents targeting tumour vessel growth have potential activity in all subtypes of breast cancer, and therefore are not considered a targeted approach for triple-negative tumours alone. Due to specific defects in DNA-damage repair, basal-like cancers depend on alternative, more error-prone repair pathways. Currently, scientific interest is focussing on drugs blocking those mechanisms. PARP-1 inhibitors, in conjunction with platinum derivatives, were found to exhibit significant survival benefit over chemotherapy alone even in a relatively small phase II study. For the first time, this approach offers the chance of highly active, specific therapy for triple-negative disease.
authors.affiliation: Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, Vienna, Austria. rupert.bartsch@meduniwien.ac.at
authors.forename: Rupert
authors.initials: R
authors.lastname: Bartsch
authors.forename: Reinhard
authors.initials: R
authors.lastname: Ziebermayr
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Zielinski
authors.forename: Guenther G
authors.initials: GG
authors.lastname: Steger
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004249:DNA Damage / Q000235:genetics*; D004260:DNA Repair / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D008408:Mastectomy; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000401:mortality / Q000517:prevention & control; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D020411:Oligonucleotide Array Sequence Analysis; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D011960:Receptors, Estrogen / Q000235:genetics*; D011980:Receptors, Progesterone / Q000235:genetics*; D012307:Risk Factors
chemical_list: D005819:Genetic Markers; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C499320:PARP1 protein, human; C508053:ERBB2 protein, human
references.citation: N Engl J Med. 2006 Aug 10;355(6):560-9
references.pmid: 16899776
references.citation: Breast Cancer Res Treat. 2008 May;109(1):123-39
references.pmid: 17578664
references.citation: Nat Med. 1996 Jan;2(1):72-9
references.pmid: 8564846
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Breast Cancer Res. 2008;10(6):R101
references.pmid: 19055754
references.citation: Breast Cancer Res Treat. 2009 May;115(2):359-63
references.pmid: 18649131
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4286-93
references.pmid: 21990397
references.citation: Ann Oncol. 2009 Nov;20(11):1771-85
references.pmid: 19608616
references.citation: J Clin Oncol. 2007 May 20;25(15):2012-8
references.pmid: 17513805
references.citation: Cancer Sci. 2008 Feb;99(2):376-84
references.pmid: 18201278
references.citation: Hum Pathol. 2006 Sep;37(9):1217-26
references.pmid: 16938528
references.citation: Breast Cancer Res. 2007;9(6):404; author reply 405
references.pmid: 18279542
references.citation: Mod Pathol. 2006 Feb;19(2):264-71
references.pmid: 16341146
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):130-5
references.pmid: 11136250
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97
references.pmid: 17255270
references.citation: Nature. 2005 Apr 14;434(7035):917-21
references.pmid: 15829967
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1810-6
references.pmid: 18347007
references.citation: Ann Oncol. 2008 Nov;19(11):1847-52
references.pmid: 18567607
references.citation: J Clin Oncol. 2009 Jan 1;27(1):11-5
references.pmid: 19047293
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Cancer. 2007 Aug 15;110(4):876-84
references.pmid: 17620276
references.citation: Science. 1987 Jan 23;235(4787):442-7
references.pmid: 2432664
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references.pmid: 17671126
references.citation: Cell Cycle. 2006 May;5(9):1001-7
references.pmid: 16639080
references.citation: Ann Oncol. 2009 Jul;20(7):1185-92
references.pmid: 19218307
references.citation: BMC Genomics. 2007 Jul 31;8:258
references.pmid: 17663798
references.citation: Science. 1994 Oct 7;266(5182):120-2
references.pmid: 7939630
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5020-5
references.pmid: 19671869
references.citation: Cancer Cell. 2005 Oct;8(4):299-309
references.pmid: 16226705
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: Oncogene. 2007 Mar 29;26(14):2126-32
references.pmid: 17016441
references.citation: Invest New Drugs. 2011 Feb;29(1):182-8
references.pmid: 19756376
references.citation: Oncogene. 2006 Sep 25;25(43):5854-63
references.pmid: 16998500
references.citation: BMC Cancer. 2007 Jul 24;7:134
references.pmid: 17650314
references.citation: J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
references.pmid: 14519755
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references.pmid: 18316557
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references.pmid: 19786658
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5544-52
references.pmid: 18955454
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1252-60
references.pmid: 21383283
references.citation: J Clin Oncol. 2005 Feb 1;23(4):792-9
references.pmid: 15681523
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347